BioStem Technologies (BSEM) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioStem Technologies (BSEM) has outperformed Metagenomi Therapeutics (MGX) over the past year, losing 50.5% versus a loss of 66.6%. BioStem Technologies is the larger company by market cap ($44.6 million vs $37.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | MGX |
|---|---|---|
| Share price | $2.39 | $0.9847 |
| Market cap | $44.63M | $37.20M |
| 1-day change | -3.24% | -4.40% |
| YTD return | -37.27% | -39.22% |
| 1-year return | -50.52% | -66.62% |
| 5-year return | +70.71% | — |
| P/E ratio (TTM) | 2.72 | — |
| Forward P/E | 8.24 | — |
| EPS (TTM) | $0.88 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $3.95 |
| 52-week low | $2.25 | $0.96 |
| Distance from 52-week high | -71.55% | -75.07% |
| Average volume | 120.39K | 155.71K |
| Shares outstanding | 18.67M | 37.78M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BSEM has outperformed MGX by 16.1 percentage points over the past year.
BSEM vs MGX FAQ
Which is bigger, BioStem Technologies or Metagenomi Therapeutics?
BioStem Technologies (BSEM) is larger, with a market capitalization of $44.63M compared with $37.20M for Metagenomi Therapeutics (MGX).
Which stock has performed better over the past year, BSEM or MGX?
BSEM returned -50.52% over the past 12 months, compared with -66.62% for MGX (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.